Patent details
EP1409018 Title: STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION THE IGG ANTIBODY DACLIZUMAB
Basic Information
- Publication number:
- EP1409018
- PCT Application Number:
- PCT/US/2002/024078
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP027592062
- PCT Publication Number:
- WO/2003/009817
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION THE IGG ANTIBODY DACLIZUMAB
- French Title of Invention:
- FORMULATION PHARMACEUTIQUE LYOPHILISEE STABLE D'ANTICORPS IGG DACLIZUMAB
- German Title of Invention:
- STABILE LYOPHILISIERTE PHARMAZEUTISCHE FORMULIERUNG DES IGG-ANTIKÖRPERS DACLIZUMAB
- SPC Number:
Dates
- Filing date:
- 25/07/2002
- Grant date:
- 06/01/2010
- EP Publication Date:
- 06/01/2010
- PCT Publication Date:
- 06/02/2003
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 21/04/2004
- EP B1 Publication Date:
- 06/01/2010
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 25/07/2010
- Expiration date:
- 25/07/0015
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 25/07/2002
- Name:
- Facet Biotech Corporation
- Address:
- 1400 Seaport Boulevard, Redwood City, California 94063, United States (US)
Inventor
1
- Name:
- FLORES-NATE Aleni
- Address:
- United States (US)
2
- Name:
- GUPTA Supriya
- Address:
- United States (US)
3
- Name:
- KAISHEVA Elizabet, A.
- Address:
- United States (US)
Priority
- Priority Number:
- 307878 P
- Priority Date:
- 25/07/2001
- Priority Country:
- United States (US)
Classification
- Main IPC Class:
- A61K 9/19;
| Filing date | Document type | Number of pages |
|---|